What changed in the IBRX analyst rating on February 23, 2026?

On February 23, 2026 Goldman Sachs and H.C. Wainwright **maintained Buy** on ImmunityBio. H.C. Wainwright also raised its **price target to $15** from $10, reinforcing a positive analyst bias for IBRX analyst rating.

How should investors interpret the H.C. Wainwright price target raise?

The raise to **$15** signals stronger upside assumptions from H.C. Wainwright. Investors should view it as increased analyst confidence but confirm assumptions against trial timelines and cash runway when assessing the IBRX analyst rating.

Does the maintained Buy mean IBRX stock will rise soon?

A maintained Buy is an analyst view, not a timing signal. It suggests upside over a medium term. Short-term moves can still go against analysts, so pair the IBRX analyst rating with catalysts and risk checks.

What is Meyka AI's current assessment of IBRX?

Meyka AI rates IBRX with a **B+**. This grade blends sector performance, financial growth, analyst consensus, and benchmark comparisons but is not financial advice for trading based on the IBRX analyst rating.

Analyst Ratings

Goldman Sachs, H.C. Wainwright Maintain Buy on ImmunityBio, Inc. (IBRX) Feb 2026

ByDanny Kontos February 24, 2026February 24, 2026

IBRX analyst rating: Goldman Sachs and H.C. Wainwright maintained Buy on ImmunityBio, Inc. (IBRX) on February 23, 2026. The dual maintenance keeps consensus support steady while H.C. Wainwright raised its price target to $15 from $10. The actions arrive alongside recent share weakness of roughly -12%, which frames the analyst views as endorsements rather than momentum calls. We examine the rating details, price target change, firm rationales, and what these updates mean for investors monitoring IBRX analyst rating as part of their research.